-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Tops Q3 EPS by 4c
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Misses Q2 EPS by 3c ; Provides Outlook
-
-
-
-
-
-
-
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
-
-
-
-
-
-
-
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
-
-
-
-
-
-
-
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

